ClinicalTrials.gg
RecruitingNCT07223229Updated Nov 2, 2026

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

A Phase 2 interventional study of EI-001 and Placebo in Non-segmental Vitiligo, sponsored by Elixiron Immunotherapeutics (Hong Kong) Ltd.. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Elixiron Immunotherapeutics (Hong Kong) Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.
Updated Nov 2, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Vitiligo with a site in United States — 13 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Planned enrollment
32nd of 68
45 · median 37
Started
2025
with 4 others
Phase 2
31 of 80
5 open now
Primary completion
2026-12
later than 6 of 23 live
Registered
75th of 80
by date

Among the 80 studies in Vitiligo with a site in United States, this one is the 32nd largest by planned enrollment of the 68 interventional ones that give a count, is one of 5 that started in 2025, is one of 31 in phase 2, reaches primary completion later than 6 of the 23 other live ones, and was the 75th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 95 are open to participants now.

Browse Vitiligo studies →

Open to participants now

13 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Vitiligo studies recruiting now, 13 (28%) set no upper age limit and 28 (60%) stop at 75 or younger; 17 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.

03

Conditions studied

  • Non-segmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and voluntarily sign the form (ICF).
  • Male or female, aged 18-65 years at the time of consent.
  • 18-38 kg/m² and weight ≥ 40 kg at consent. Clinically diagnosed non-segmental vitiligo (NSV) for at least 3 months, and meets one of the following:
  • Inadequate response to approved treatments:
  • Topical therapy (e.g., , calcineurin inhibitors, or JAK inhibitors) ≥ 3 months,
  • Phototherapy ≥ 6 months, or Oral therapy (e.g., corticosteroids, calcineurin inhibitors) ≥ 3 months.
  • Or unable to use these treatments due to , intolerance, or unsuitability.
  • Depigmentation extent meeting all of the following:

Facial BSA (F-BSA) ≥ 0.5%, Facial VASI (F-VASI) ≥ 0.5, Total BSA (T-BSA) between 5% and 60%, Total VASI (T-VASI) ≥ 5.

  • Agree to discontinue all vitiligo treatments from screening until final follow-up.
  • If not previously vaccinated against zoster, agree to complete vaccination before Day 1.
  • Not applicable to females of non- (surgically sterile or ≥12 months, confirmed by FSH at screening).

Exclusion criteria

Exclusion Criteria:

  • Non-eligible skin conditions: Other types of vitiligo (e.g., segmental) or other depigmentation disorders (e.g., piebaldism, leprosy, post-inflammatory hypopigmentation, tinea versicolor, etc.), or ≥30% leukotrichia on face or body.
  • Psychiatric risk
  • Recent vitiligo treatments
  • Surgical treatments or depigmenting agents (e.g., monobenzone)
  • High-dose
  • Pregnancy or lactation
  • Abnormal Medical conditions
  • Prohibited prior therapies
  • Cardiac abnormalities
  • Abnormal chest X-ray
  • Renal impairment
  • abnormal laboratory results at screening, per investigator judgment.
  • Viral infections:
  • : Known allergy or severe reaction to EI-001 or its .
  • Compliance concerns: Any condition that would make it difficult for the subject to follow the study schedule, receive treatment, attend visits, or could interfere with study objectives, data interpretation, or participant safety.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Drug: EI-001

    Biological: EI-001

  • Placebo comparator
    Drug: Placebo

    Other: Placebo

Interventions

  • BiologicalEI-001

    EI-001 drug product is supplied as a colorless to slightly yellow and sterile solution for infusion with a protein concentration of 10.0 mg/mL

  • OtherPlacebo

    0.9% sterile sodium chloride solution

06

What researchers measure

Primary outcomes

  1. Percent change in F-VASI from baseline

    Time frame: Week 24

Secondary outcomes

  1. Proportion of subjects achieving F-VASI50

    F-VASI50 is defined as at least 50% improvement in F-VASI from baseline

    Time frame: Week 24

  2. Frequency and severity of AEs and SAEs

    Including the results of physical examinations, vital signs, evaluation of clinical laboratory studies, and ECG

    Time frame: Week 32

  3. Absolute values and percent change in F-VASI from baseline at designated time points

    Time frame: Week 22

  4. Absolute values and percent change in T-VASI from baseline at designated time points

    Time frame: Week 22

  5. Proportion of subjects achieving F-VASI50/75, T-VASI50 at designated time points

    F-VASI75 is defined as at least 75% improvement in F-VASI from baseline T-VASI50 is defined as at least 50% improvement in T-VASI from baseline

    Time frame: Week 22

07

Study locations

7 of 8 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 45 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2025
First posted
Oct 31, 2025
StartActual
Dec 30, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Sep 30, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 United States, 1 Taiwan)
  • Apex Clinical Research Center (Lorain) · Lorain, United States
  • Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwan
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    2 sites added
    Show 2 added (1 United States, 1 Taiwan)
    • Apex Clinical Research Center (Lorain) · Lorain, United States
    • Chang Gung Medical Foundation Kaohsiung Chang Gung Memorial Hospital · Kaohsiung City, Taiwan

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07223229
Lead sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Responsible party
Sponsor
First posted
Oct 31, 2025
Start date
Dec 30, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Nov 2, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion